Salarius and Decoy Announce Merger in Biopharmaceutical Innovation

Salarius Pharmaceuticals and Decoy Therapeutics have announced a definitive merger agreement, creating a combined entity that plans to leverage advanced technologies to further its efforts in developing peptide conjugate therapeutics. This merger, valued at an estimated $7 million from various funding sources, including the Bill & Melinda Gates Foundation, aims to target respiratory viruses and cancer. As part of the merger strategy, the new entity will integrate Salarius' current therapeutic developments into Decoy's innovative AI and ML-driven drug discovery platforms. Executive leadership will comprise Decoy's key figures alongside Salarius' CFO, ensuring a robust governance structure post-merger. With multiple drug candidates under development, the transaction promises to advance clinical trials and broaden therapeutic pipelines addressing unmet medical needs. The definitive agreement awaits shareholder approval for conversion of preferred stock into common stock. The merger is poised to create significant value by leveraging the newly combined capabilities and resources.